KRAS G12C is the driving oncogenic mutation in ~10% of all non-small cell lung cancer (NSCLC) patients. The first inhibitor targeting this mutation was recently approved for the treatment of locally advanced or metastatic NSCLC. While this inhibitor targets the tumor cells specifically, changes in the immune infiltrate have been observed.
In this webinar, Dr. Febe van Maldegem of Dr. Julian Downward's group at The Francis Crick Institute, will discuss the group's development of an Imaging Mass Cytometry (IMC) workflow that enables them to phenotypically and spatially characterize the tumor microenvironment (TME) in mouse tissues. Using this approach, they have shown how targeted KRAS G12C inhibition leads to a dramatic remodeling of the lung tumor microenvironment.